Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment
- 24 December 2009
- journal article
- research article
- Published by Taylor & Francis Ltd in Scandinavian Journal of Gastroenterology
- Vol. 45 (3), 325-331
- https://doi.org/10.3109/00365520903483650
Abstract
Objective. Serial monitoring data for faecal calprotectin and lactoferrin during Crohn's disease (CD) therapy are scarce. The aim of this research was to study the behaviour of faecal biomarkers during CD therapy. Material and methods. Adult CD patients (n = 19) needing therapy enhancement were prospectively recruited. The simple endoscopic score for Crohn's disease (SES-CD) was administered before and 4–6 months after therapy. At baseline and at 2–3 and 4–6 months, patients provided faecal samples for measurements of calprotectin and lactoferrin. Results. Of 19 patients, seven were endoscopic responders, three were partial responders and nine were non-responders. During therapy, both faecal-biomarker concentrations decreased significantly in responders: median calprotectin from 1282 μg/g (range 156–2277 μg/g) to 73 μg/g (range 7–2222; P = 0.005) and lactoferrin from 233 μg/g (range 2.8–802 μg/g) to 0.0 μg/g (range 0.0–420 μg/g; P = 0.005), and these changes correlated significantly with changes in the SES-CD. In non-responders, changes in faecal biomarkers were non-significant: calprotectin decreased from 1017 μg/g (range 53–3928 μg/g) to 223 μg/g (range 35–15 330 μg/g; P = 0.594) and lactoferrin from 22.5 μg/g (range 2.1–629 μg/g) to 13.0 μg/g (range 3.5–1259 μg/g; P = 0.515). Conclusions. The faecal neutrophil-derived proteins calprotectin and lactoferrin are reliable surrogate markers of mucosal improvement. Endoscopic responders achieved normalization of faecal biomarkers, whereas in the majority of endoscopic non-responders these markers remained abnormal.Keywords
This publication has 34 references indexed in Scilit:
- Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel diseaseWorld Journal of Gastroenterology, 2008
- Fecal Lactoferrin Is a Sensitive and Specific Marker of Disease Activity in Children and Young Adults With Inflammatory Bowel DiseaseJournal of Pediatric Gastroenterology and Nutrition, 2007
- Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel diseaseScandinavian Journal of Gastroenterology, 2006
- Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel diseaseScandinavian Journal of Gastroenterology, 2004
- Crohn's disease: monitoring disease activityAlimentary Pharmacology & Therapeutics, 2003
- Fecal Lactoferrin Is A Sensitive and Specific Marker in Identifying Intestinal InflammationThe American Journal of Gastroenterology, 2003
- A simple method for assessing intestinal inflammation in Crohn's diseaseGut, 2000
- High prevalence of NSAID enteropathy as shown by a simple faecal testGut, 1999
- Correlation between Faecal Excretion of Indium-111-Labelled Granulocytes and Calprotectin, a Granulocyte Marker Protein, in Patients with Inflammatory Bowel DiseaseScandinavian Journal of Gastroenterology, 1999
- Clinical Remission in Crohn’s Disease – Assessment Using Faecal 111ln Granulocyte ExcretionDigestion, 1986